SynthesisJournal of cardiothoracic surgery2024
Prognostic value of albumin-bilirubin grade in lung cancer: a meta-analysis.
Synthesis in Journal of cardiothoracic surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic Value of albumin-bilirubin (ALBI) Grade in Patients with Gastric Cancer: A Systematic Review and meta-analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Serum Bilirubin as a Prognostic Factor in Lung Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Prognostic Significance of Albumin-Bilirubin (ALBI) Score in Gastric Cancer Patients Undergoing Curative Resection Followed by Adjuvant Therapy.Medicina (Kaunas, Lithuania) · 2026Article
- Impact of Serum Albumin Levels on Prognosis and Recurrence in Patients with Hepatocellular Carcinoma.Cancers · 2025Article
- Usefulness of White Blood Cell Differential-based Indices in Patients With Extensive-stage Small Cell Lung Cancer.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo clarify the prognostic role of pretreatment albumin-bilirubin (ALBI) grade in lung cancer patients.
methodsThe PubMed, EMBASE, Web of Science and CNKI databases were searched up to April 20, 2024. Primary outcomes included the overall survival (OS), progression-free survival (PFS) and cancer-specific survival (CSS). Hazard ratios (HRs) with 95% confidence intervals (CIs) were combined and subgroup analysis based on the type of lung cancer [non-small cell lung cancer (NSCLC) vs. small cell lung cancer (SCLC)] and treatment [surgery vs. immune checkpoint inhibitors (ICIs) vs. chemotherapy] was conducted.
resultsEight studies with 2,057 patients were included. Pooled results indicated that elevated pretreatment ALBI grade was significantly related to poor OS (HR = 2.50, 95% CI: 2.03-3.09, P<0.001), PFS (HR = 1.91, 95% CI: 1.56-2.33, P<0.001) and CSS (HR = 1.90, 95% CI: 1.11-3.11, P = 0.018). Subgroup analysis for OS based on the pathological type and primary treatment manifested similar results.
conclusionPretreatment ALBI grade is associated with prognosis in lung cancer and patients with elevated ALBI grade are more likely to experience worse survival.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.